Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting

AIDS Patient Care and STDs

Volumn 26, Issue 1, 2012, Pages 60-67

  Milloy, M J ^a,b   Kerr, Thomas ^a,b   Bangsberg, David R ^c,d   Buxton, Jane ^b,e   Parashar, Surita ^a   Guillemi, Silvia ^a   Montaner, Julio ^a,b   Wood, Evan ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ILLICIT DRUG;

ADULT; ARTICLE; CANADA; DISEASE ASSOCIATION; DRUG ABUSE; FEMALE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CANADA; COHORT STUDIES; DRUG USERS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV SEROPOSITIVITY; HOMELESS PERSONS; HUMANS; MALE; MEDICATION ADHERENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84555188169     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0169     Document Type: Article

References (59)

1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of anti-retroviral therapy. JAMA 1998;279:450-454. (Pubitemid 28082255)
2. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 se-roconversion after the introduction of HAART. Lancet 2003; 362:1267-1274. (Pubitemid 37324254)
3. Shannon K, Bright V, Duddy J, Tyndall MW. Access and utilization of HIV treatment and services among women sex workers in Vancouver's downtown eastside. J Urban Health 2005;82:488-497. (Pubitemid 41191567)
4. Stein MD, Rich JD, Maksad J, et al. Adherence to anti-retroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000;26:195-205. (Pubitemid 30366625)
5. Krüsi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among in-jection drug users. Int J Drug Pol 2010;21:4-9.
6. Allen DM, Lehman JS, Green TA, Lindegren ML, Onorato IM, Forrester W. HIV infection among homeless adults and runaway youth, United States, 1989-1992. Field Services Branch. AIDS 1994;8:1593-1598. (Pubitemid 24335097)
7. Robertson MJ, Clark RA, Charlebois ED, et al. HIV ser-oprevalence among homeless and marginally housed adults in San Francisco. Am J Public Health 2004;94:1207-1217 (Pubitemid 38857325)
8. Torres RA, Mani S, Altholz J, Brickner PW. Human immu-nodeficiency virus infection among homeless men in a New York City shelter. Association with Mycobacterium tuber-culosis infection. Arch Intern Med 1990;150:2030-2036. (Pubitemid 20348352)
9. Smith MY, Rapkin BD, Winkel G, Springer C, Chhabra R, Feldman IS. Housing status and health care service utiliza-tion among low-income persons with HIV/AIDS. J Gen In-tern Med 2000;15:731-738.
10. Fichter MM, Quadflieg N. Prevalence of mental illness in homeless men in Munich, Germany: Results from a repre-sentative sample. Acta Psychiatr Scand 2001;103:94-104. (Pubitemid 32147129)
11. Das-Douglas M, Colfax G, Moss AR, Bangsberg DR, Hahn JA. Tripling of methamphetamine/amphetamine use among homeless and marginally housed persons, 1996-2003. J Ur-ban Health 2008;85:239-249.
12. Kushel MB, Hahn JA, Evans JL, Bangsberg DR, Moss AR Revolving doors: Imprisonment among the homeless and marginally housed population. Am J Public Health 2005;95: 1747-1752. (Pubitemid 41369044)
13. Heslin KC, Robinson PL, Baker RS, Gelberg L. Community characteristics and violence against homeless women in Los Angeles County. J Health Care Poor Underserved 2007;18: 203-218.
14. Buchér JB, Thomas KM, Guzman D, Riley E, Dela Cruz N, Bangsberg DR. Community-based rapid HIV testing in homeless and marginally housed adults in San Francisco. HIV Med 2007;8:28-31. (Pubitemid 46117838)
15. Aidala AA, Lee G, Abramson DM, Messeri P, Siegler A. Housing need, housing assistance, and connection to HIV medical care. AIDS Behav 2007;11(6 Suppl):101-115.
16. Leaver CA, Bargh G, Dunn JR, Hwang SW. The effects of housing status on health-related outcomes in people living with HIV: A systematic review of the literature. AIDS Behav 2007;11(6 Suppl):85-100.
17. Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incom-plete HIV RNA suppression among homeless and margin-ally housed HIV-infected individuals in San Francisco. J Gen Intern Med 2009;24:14-20.
18. Galea S, Vlahov D. Social determinants and the health of drug users: Socioeconomic status, homelessness, and incar-ceration. Public Health Rep 2002;117(Suppl 1):S135-145. (Pubitemid 35351227)
19. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14: 357-366. (Pubitemid 30182431)
20. Knowlton AR, Arnsten JH, Eldred LJ, et al. Antiretroviral use among active injection-drug users: The role of patient-provider engagement and structural factors. AIDS Patient Care STDs 2010;24:421-428.
21. Lehavot K, Huh D, Walters KL, King KM, Andrasik MP, Simoni JM. Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence. AIDS Patient Care STDs 2011;25:181-189.
22. Moss A, Hahn J, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Fran-cisco: A prospective study. Clin Infect Dis 2004;39:1190-1198. (Pubitemid 40169319)
23. Weiser SD, Bangsberg DR, Kegeles S, Ragland K, Kushel MB, Frongillo EA. Food insecurity among homeless and marginally housed individuals living with HIV/AIDS in San Francisco. AIDS Behav 2009;13:841-848.
24. Nolan S, Milloy MJ, Zhang R, et al. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care (in press).
25. Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Home-lessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health 2011;88:545-555.
26. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-549. (Pubitemid 28377675)
27. Wood E, Hogg RS, Bonner S, et al. Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004;292: 1175-1177. (Pubitemid 39167404)
28. Wood E, Hogg RS, Lima VD, et al. Highly active anti-retroviral therapy and survival in HIV-infected injection drug users. JAMA 2008;300:550-554.
29. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that pre-cludes a survival response to modern antiretroviral therapy? AIDS 2003;17:711-720. (Pubitemid 36521077)
30. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350·10(9) cells/L. Ann Intern Med 2003;139:810-816.
31. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-361. (Pubitemid 30327043)
32. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected pa-tients with and without a history of injection drug use. AIDS 2001;15:423-424. (Pubitemid 32163834)
33. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003;169: 656-661. (Pubitemid 37266973)
34. Maldonado G, Greenland S. Simulation study of confound-er-selection strategies. Am J Epidemiol 1993;138:923-936.
35. Rothman KJ, Greenland S. Modern Epidemiology. New York: Lippincott Williams & Wilkins, 1998.
36. Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med 2009;68:1044-1049.
37. Marshall BD, Kerr T, Shoveller JA, Patterson TL, Buxton JA, Wood E. Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place 2009;15:753-760.
38. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-1182.
39. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gour-evitch MN, Arnsten JH. Gender differences in factors asso-ciated with adherence to antiretroviral therapy. J Gen Intern Med 2004;19:1111-1117 (Pubitemid 39552581)
40. Carballo E, Cadarso-Suárez C, Carrera I, et al. Assessing re-lationships between health-related quality of life and adher-ence to antiretroviral therapy. Qual Life Res 2004;13:587-599. (Pubitemid 38526534)
41. Kidder DP, Wolitski RJ, Campsmith ML, Nakamura GV. Health status, health care use, medication use, and medica-tion adherence among homeless and housed people living with HIV/AIDS. Am J Public Health 2007;97:2238-2245. (Pubitemid 351194704)
42. Parruti G, Manzoli L, Toro PM, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: Predictors and impact on virologic response and relapse. AIDS Patient Care and STDs 2006;20:48-56.
43. Das-Douglas M, Riley ED, Ragland K, et al. Implementation of the Medicare Part D Prescription Drug Benefit is associated with antiretroviral therapy interruptions. AIDS Behav 2009;13:1-9.
44. Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incom-plete HIV RNA suppression among homeless and margin-ally housed HIV-infected individuals in San Francisco. J Gen Intern Med 2009;24:14-20.
45. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease in-hibitors in the homeless. JAMA 1997;278:63-65.
46. Scott A, Ellen J, Clum G, Leonard L. HIV and housing as-sistance in four U.S. cities: variations in local experience. AIDS Behav 2007;11(6 Suppl):140-148.
47. Waldrop-Valverde D, Valverde E. Homelessness and psycho-logical distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care STDs 2005;19:326-334. (Pubitemid 40770656)
48. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clin Infect Dis 2004;38(Suppl 5):S376-387. (Pubitemid 38738534)
49. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002;11:271-278. (Pubitemid 35332504)
50. Garland WH, Wohl AR, Valencia R, et al. The acceptability of a directly-administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California. AIDS Care 2007;19:159-167.
51. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 2007;21:1473-1477. (Pubitemid 46988008)
52. Maru DS-R, Bruce RD, Walton M, et al. Initiation, adherence, and retention in a randomized controlled trial of directly ad-ministered antiretroviral therapy. AIDS Behav 2008;12:284-293.
53. Wolitski RJ, Kidder DP, Pals SL, et al. Randomized trial of the effects of housing assistance on the health and risk be-haviors of homeless and unstably housed people living with HIV. AIDS Behav 2010;14:493-503.
54. Schwarcz SK, Hsu LC, Vittinghoff E, Vu A, Bamberger JD, Katz MH. Impact of housing on the survival of persons with AIDS. BMC Public Health 2009;9:220.
55. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and anti-retroviral therapy: Systematic review and meta-analysis. AIDS 2009;23:1397-1404.
56. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006;368:531-536. (Pubitemid 44142776)
57. Wood E, Kerr T, Marshall BD, et al. Longitudinal commu-nity plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: Prospective cohort study. BMJ 2009;338:b1649.
58. Aidala A, Cross JE, Stall R, Harre D, Sumartojo E. Housing status and HIV risk behaviors: Implications for prevention and policy. AIDS Behav 2005;9:251-265. (Pubitemid 41584978)
59. Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: Epidemiology and impact on antiretroviral therapy. Drugs 2006;66:769-789. (Pubitemid 43765224)